CCRM

08/31/2026

Canada has invested heavily in infrastructure. Now, we need to ensure it’s being put to work. CCRM and are helping companies move from innovation to clinical manufacturing with commercial scale in mind from day one. MaRS Discovery District,

Learn why increased biomanufacturing capacity is vital for Canada’s economy and its ability to produce critical healthcare products.

08/31/2026

Time is running out to submit your 2026 Cells I See art contest entries!

Hosted by CCRM and the Stem Cell Network - Réseau de cellules souches, the Cells I See art contest is accepting submissions until this Friday only (September 4). Cells I See is about the beauty of cells seen directly through the microscope or through the interpretive lens of the artist.

Based on the outcome of online voting on CCRM’s page, a People’s Choice prize of $500 will be issued. Entries will also be blind judged at the 2026 Till & McCulloch Meetings to determine the $750 Grand Prize winner.

For full contest rules, submission instructions and to view past submissions, check out the Cells I See website here: https://cellsisee.ccrm.ca/

08/24/2026

https://themedicinemaker.com/issues/2026/articles/august/the-biggest-bottlenecks-holding-back-cell-and-gene-therapy/

Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges

08/24/2026

Time is running out to submit your 2026 Cells I See art contest entries!

Hosted by CCRM and the Stem Cell Network - Réseau de cellules souches, the Cells I See art contest is accepting submissions until September 4. Cells I See is about the beauty of cells seen directly through the microscope or through the interpretive lens of the artist.

Based on the outcome of online voting on CCRM’s page, a People’s Choice prize of $500 will be issued. Entries will also be blind judged at the 2026 Till & McCulloch Meetings to determine the $750 Grand Prize winner.

For full contest rules, submission instructions and to view past submissions, check out the Cells I See website here: https://cellsisee.ccrm.ca/

, , ,

08/21/2026

Canada can build globally competitive companies, but can it keep them here? MaRS Discovery District makes a good argument that we have the ingredients in place, especially in cell and gene therapy.

There’s good news in the health tech sector. After several difficult years globally, investors are once again backing ambitious healthcare companies. Capital is flowing back into the sector, deals are increasing in both size and number and funding has improved across most major markets. In Canada,...

08/19/2026

If you have thought about launching a cell and gene therapy company, read this post for valuable insights.

Venture by Design: What it really takes to build viable companies in CGT

https://www.signalsblog.ca/venture-by-design-what-it-really-takes-to-build-viable-companies-in-cgt/

08/14/2026

CMC is often associated with regulatory compliance, but the companies that excel in cell and gene therapy know it's much more than that.

On the latest episode of Commercializing Living Therapies with CCRM, host Krista Lamb-Davidson speaks with Katy Spink, Dark Horse Consulting Group, and Craig Beasley, BlueRock Therapeutics, about why Chemistry, Manufacturing and Controls (CMC) can be a true competitive advantage.

They discuss:
✅ What CMC really means in the context of cell and gene therapies
✅ Why CMC strategy should begin long before commercialization
✅ How to balance in-house expertise with consultants, CDMOs and strategic partners
✅ What regulators expect today, and how those expectations are evolving
🚫The common mistakes companies make when they underinvest in CMC, and how to avoid them

Whether you’re leading an early-stage biotech, supporting technology commercialization or working in advanced therapies, this episode offers practical insights into building a stronger path to patients.

Listen at the link below, or find it wherever you stream podcasts.

https://www.ccrm.ca/podcast/

08/12/2026

The 2026 Cells I See art contest is accepting cell images and artwork submissions from now until Friday, September 4, 2026. Cells I See is about the beauty of cells seen directly through the microscope or through the interpretive lens of the artist.

Hosted by CCRM and the Stem Cell Network - Réseau de cellules souches, the Cells I See art contest will award $750 to the Grand Prize winner, based on blind judging at the 2026 Till & McCulloch Meetings in Vancouver, Canada, in November. Plus, a People’s Choice prize of $500 will be issued based on the outcome of voting on CCRM’s page (more details to follow).

For full contest rules, submission instructions and to view past submissions, check out the Cells I See website at https://cellsisee.ccrm.ca/

08/07/2026

Why do seem to be everywhere these days? Amid the popularity of GLP-1, collagen peptides, and those used by athletes, our Signals editor explores the craze. Plus, watch a great investigative report by Idil M***a of CBC with an interview with Timothy Caulfield, University of Alberta.

https://www.signalsblog.ca/right-turn-the-real-science-real-benefits-and-real-risks-of-peptides/

cc: McGill University

07/23/2026

Breakthrough science only changes lives if patients can receive it. As more advanced therapies reach the clinic, Canada needs reimbursement systems that move as quickly as innovation.

Read, "Approval isn't access: Why reimbursement matters for advanced therapies"

https://www.signalsblog.ca/approval-isnt-access-why-reimbursement-matters-for-advanced-therapies/

The Globe and Mail, Stem Cell Network - Réseau de cellules souches